Soin Neuroscience

What Soin Neuroscience does

Soin Neuroscience is a privately held medical device company based in Dayton, Ohio, founded in 2016, that specialized in spinal cord stimulation (SCS) technology for chronic pain management. The company developed proprietary intellectual property covering SCS waveform design, adaptive programming algorithms, and machine learning applications for personalized neuromodulation therapy. Its core technology targeted treatment-resistant chronic pain through personalized SCS tuning designed to improve patient outcomes relative to conventional stimulation approaches.

The company's business model centered on intellectual property licensing and research collaborations rather than direct device commercialization. In July 2026, BIOTRONIK Neuro acquired Soin Neuroscience's SCS IP portfolio, including patents on waveform design, adaptive programming, and AI/ML applications for neuromodulation, for integration into BIOTRONIK's Prospera SCS platform. Following this divestiture, Soin Neuroscience continues to operate independently with a small team of 11-50 employees and is now pursuing alternative pain management technologies, including a research collaboration with Lilac Biosciences focused on RNA expression biomarkers for neuropathic pain assessment and neuromodulation response.

The company serves two primary segments: healthcare providers and health systems offering chronic pain management services (historically via its SCS technology now licensed to BIOTRONIK), and research institutions studying pain mechanisms and neuromodulation therapies. Go-to-market activity has been conducted through enterprise B2B channels, including industry conferences, peer-reviewed publications, and strategic partnerships with larger medical device and diagnostics companies. Pricing is not publicly disclosed, and revenue mechanics appear to rely on IP licensing royalties and research collaboration fees rather than direct product sales.

Name

Soin Neuroscience

Legal name

Soin Neuroscience

Website

https://soinneuroscience.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Soin Neuroscience is a Dayton, Ohio-based medical device company that developed spinal cord stimulation technology for chronic pain management. Its SCS IP portfolio was acquired by BIOTRONIK Neuro in 2026; the company now operates independently, pursuing RNA biomarker research with Lilac Biosciences.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industry

Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)

Keywords

• Spinal cord stimulation
• Neuromodulation therapy
• Chronic pain management
• Adaptive programming algorithms
• Medical device research

Headquarters

HQ city

Dayton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. IP Licensing and Technology Transfer: Revenue generated from licensing spinal cord stimulation intellectual property to larger medical device companies. BIOTRONIK Neuro acquired the SCS IP portfolio from Soin Neuroscience, suggesting a technology licensing model.
2. Research Collaborations: Revenue from research collaborations with partners including Lilac Biosciences for RNA biomarker research in pain and neuromodulation
3. Neuromodulation Device Technology: Potential hardware and technology sales related to spinal cord stimulation devices and related pain management technologies

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Soin Neuroscience develops spinal cord stimulation (SCS) intellectual property for chronic pain management, including proprietary waveform designs, adaptive programming algorithms, and AI/machine learning applications for personalized neuromodulation therapy. The company licenses and transfers its SCS IP portfolio to established medical device manufacturers (e.g., BIOTRONIK Neuro) and conducts collaborative research on RNA biomarkers for pain assessment with partners such as Lilac Biosciences. Following the July 2026 sale of its SCS IP portfolio, the company continues to operate independently while pursuing additional pain management technologies.

Product overview

Soin Neuroscience is a medical device company based in Dayton, Ohio, specializing in spinal cord stimulation (SCS) technology for chronic pain management. The company developed neuromodulation therapy featuring waveform design, adaptive programming, and AI/machine learning applications. Soin Neuroscience sold its SCS intellectual property portfolio to BIOTRONIK Neuro but continues operating independently while pursuing other pain management technologies and research collaborations. The company is also engaged in research collaborations studying RNA biomarkers for neuropathic pain assessment and neuromodulation response.

Differentiator

Problem solved

Functional benefit

Products and services

• Spinal Cord Stimulation (SCS) IP Portfolio A portfolio of intellectual property covering proprietary waveform designs, adaptive programming algorithms, and machine learning applications for spinal cord stimulation therapy in chronic pain management. Licensed and subsequently acquired by BIOTRONIK Neuro for integration into their Prospera SCS system.
• RNA Biomarker Pain Assessment Research Program Collaborative research program with Lilac Biosciences focused on RNA expression analysis as biological correlates of pain states and neuromodulation response, including joint publications in Frontiers in Pain Research on RNA biomarkers for neuropathic pain assessment.

Quantifiable outcome

• Collaboration with Lilac Biosciences developing RNA biomarker framework for pain assessment and treatment monitoring
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Lilac BiosciencescoreStrategic or Co-development Partner · 1 July 2026Joint clinical review published in Frontiers in Pain Research outlining a framework for using RNA biomarkers to assess and monitor neuropathic pain. The review combines Lilac's quantitative RNA workflows with Soin Neuroscience's clinical pain management and neuromodulation expertise. Builds on ongoing collaboration exploring how RNA modifications such as m6A could support pain characterization, treatment selection, and patient monitoring over time.
• BIOTRONIK NeurocoreOEM/ Whitelabel/ Licensing Partner · 1 July 2026BIOTRONIK Neuro acquired a portfolio of spinal cord stimulation intellectual property from Soin Neuroscience in July 2026. Acquired patents cover waveform design, adaptive programming, and machine learning applications for neuromodulation therapy. Transaction intended to inform development of next-generation SCS program within BIOTRONIK Neuro's chronic pain portfolio. Soin Neuroscience continues operating independently.
• Lilac BiosciencescoreStrategic or Co-development Partner · 1 February 2026Research collaboration to investigate whether changes in RNA expression can serve as biological correlates of pain states and neuromodulation response. Initial phase uses preclinical neuromodulation models to assess RNA profiles under defined spinal cord stimulation parameters, with Lilac performing RNA profiling using its quantitative RNA workflows. Partnership may extend to additional pain research programs including studies of pharmacologic interventions.
• BIOTRONIK NeurocoreStrategic or Co-development Partner · 1 December 2025Research collaboration announced December 2025 to develop personalized spinal cord stimulation tuning using Soin's waveform technology. Initiative aims to improve therapy outcomes for chronic pain patients by evaluating new stimulation algorithms and adaptive programming strategies. Collaboration explored new waveforms and personalized approaches using BIOTRONIK Neuro's Prospera SCS system.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Emerging players

• Nalu Medical: Nalu Medical is an emerging player in peripheral nerve stimulation (PNS) and SCS, focused on miniaturized neurostimulators — an adjacent category to Soin's SCS focus with overlapping waveform and personalization IP themes.
• SPR Therapeutics: SPR Therapeutics develops peripheral nerve stimulation (PNS) systems for chronic and acute pain, addressing the same chronic pain market via a neuromodulation mechanism adjacent to Soin's SCS specialty.
• Mainstay Medical: Mainstay Medical develops implantable neurostimulation systems for chronic pain (ReActiv8 for low back pain), making it an emerging peer in the broader implantable neuromodulation for chronic pain category that Soin addresses.
• Saluda Medical: Saluda Medical is an emerging neuromodulation player with its Evoke closed-loop SCS system, competing on adaptive/responsive stimulation that overlaps directly with Soin's adaptive programming and ML personalization IP.

Broad incumbents

• Boston Scientific: Boston Scientific competes in SCS through its WaveWriter and Precision platforms, targeting the same chronic pain and neuromodulation personalization use case Soin addresses with its waveform and ML IP.
• Abbott: Abbott's Proclaim SCS family competes in the same chronic pain neuromodulation segment, with overlapping investments in adaptive stimulation and patient-personalized therapy that mirror Soin's R&D focus.
• Medtronic: Medtronic is the incumbent market leader in spinal cord stimulation with its Intellis and Vanta platforms, serving the same chronic pain patient population and hospitals as Soin's addressable market, and competing for the same waveform and personalization IP direction.

Others

• Lilac Biosciences: Lilac Biosciences is Soin's research collaborator on RNA biomarker workflows for pain assessment; included as an ecosystem/thematic peer because it is the development partner on Soin's biomarker-adjacent program rather than a competing SCS vendor.

Direct peers

• Nevro Corp: Nevro is a pure-play SCS company focused on chronic pain with proprietary high-frequency 10 kHz waveform technology, directly comparable to Soin's waveform-IP differentiation strategy and chronic pain focus.
• BIOTRONIK Neuro: BIOTRONIK Neuro is a direct peer and counterparty — it commercializes the Prospera spinal cord stimulation platform that now incorporates the very SCS IP acquired from Soin Neuroscience, making it both a competitor in next-gen SCS development and Soin's primary licensing partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/soin-neuroscience-inc.

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Soin Neuroscience